Lupin soars on launching Lurasidone Hydrochloride Tablets in United States
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 668.80, up by 1.95 points or 0.29% from its previous closing of Rs. 666.85 on the BSE.
The scrip opened at Rs. 666.50 and has touched a high and low of Rs. 673.25 and Rs. 663.30 respectively. So far 11789 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 798.90 on 05-Apr-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 686.85 and Rs. 657.00 respectively. The current market cap of the company is Rs. 30435.54 crore.
The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 43.36% and 9.53% respectively.
Lupin has launched Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg, to market a generic equivalent of Latuda Tablets of Sunovion Pharmaceuticals, Inc. Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg (RLD Latuda) had estimated annual sales of $4.2 billion in the United States (IQVIA MAT December 2022).
Earlier, the company had received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its new injectable facility located in Nagpur, India.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
